NCT02649764View on ClinicalTrials.gov

Prexasertib (LY2606368), Cytarabine, and Fludarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 4, 2016

Primary Completion Date

July 12, 2022

Study Completion Date

July 12, 2022

Conditions

Chronic Myelomonocytic LeukemiaRecurrent Acute Myeloid LeukemiaRecurrent High Risk Myelodysplastic SyndromeRefractory Acute Myeloid LeukemiaRefractory High Risk Myelodysplastic Syndrome

Interventions

DRUG

Cytarabine

Given IV

DRUG

Fludarabine Phosphate

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Prexasertib

Given IV

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT02649764 - Prexasertib (LY2606368), Cytarabine, and Fludarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | Biotech Hunter | Biotech Hunter